Angiogenesis has become a major target in cancer therapy. However, current therapeutic strategies have their limitations and raise several problems. In most tumours, anti-angiogenesis treatment targeting VEGF (vascular endothelial growth factor) has only limited overall survival benefit compared with conventional chemotherapy alone, and reveals several specific forms of resistance to anti-VEGF treatment. There is growing evidence that anti-VEGF treatment may induce tumour cell invasion by selecting highly invasive tumour cells or hypoxia-resistant cells, or by up-regulating angiogenic alternative pathways such as FGFs (fibroblast growth factors) or genes triggering new invasive programmes. We have identified new genes up-regulated during glioma growth on the chick CAM (chorioallantoic membrane). Our results indicate that anti-angiogenesis treatment in the experimental glioma model drives expression of critical genes which relate to disease aggressiveness in glioblastoma patients. We have identified a molecular mechanism in tumour cells that allows the switch from an angiogenic to invasive programme. Furthermore, we are focusing our research on alternative inhibitors that act, in part, independently of VEGF. These are endogenous molecules that play a role in the control of tumour growth and may constitute a starting point for further development of novel therapeutic or diagnostic tools.
Skip Nav Destination
Article navigation
December 2011
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 21 2011
Inhibition of angiogenesis and the angiogenesis/invasion shift
Andreas Bikfalvi;
Andreas Bikfalvi
1
1University Bordeaux, LAMC, UMR 1029, F-3400 Talence, France, and INSERM, LAMC, UMR 1029, F-3400 Talence France
1To whom correspondence should be addressed (email a.bikfalvi@angio.u-bordeaux1.fr).
Search for other works by this author on:
Michel Moenner;
Michel Moenner
1University Bordeaux, LAMC, UMR 1029, F-3400 Talence, France, and INSERM, LAMC, UMR 1029, F-3400 Talence France
Search for other works by this author on:
Sophie Javerzat;
Sophie Javerzat
1University Bordeaux, LAMC, UMR 1029, F-3400 Talence, France, and INSERM, LAMC, UMR 1029, F-3400 Talence France
Search for other works by this author on:
Sophie North;
Sophie North
1University Bordeaux, LAMC, UMR 1029, F-3400 Talence, France, and INSERM, LAMC, UMR 1029, F-3400 Talence France
Search for other works by this author on:
Martin Hagedorn
Martin Hagedorn
1University Bordeaux, LAMC, UMR 1029, F-3400 Talence, France, and INSERM, LAMC, UMR 1029, F-3400 Talence France
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 12 2011
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2011 Biochemical Society
2011
Biochem Soc Trans (2011) 39 (6): 1560–1564.
Article history
Received:
September 12 2011
Citation
Andreas Bikfalvi, Michel Moenner, Sophie Javerzat, Sophie North, Martin Hagedorn; Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 1 December 2011; 39 (6): 1560–1564. doi: https://doi.org/10.1042/BST20110710
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.